

Edgar Filing: BAYER AKTIENGESELLSCHAFT - Form 6-K

BAYER AKTIENGESELLSCHAFT

Form 6-K

January 31, 2002

SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

---

FORM 6-K

Report of Foreign Issuer  
Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For the month of January, 2002

---

Bayer Aktiengesellschaft  
(Exact name of registrant as specified in its charter)

Bayerwerk, Gebaude W1  
D-51368 Leverkusen  
Germany  
(Address of principal executive offices)

---

Indicate by check mark whether the registrant files  
or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F  Form 40-F

Indicate by check mark whether the registrant by  
furnishing information contained in this Form is also  
thereby furnishing information to the  
Commission pursuant to Rule 12g3-2(b) under the Securities  
Exchange Act of 1934.

Yes  No

If "Yes" is marked, indicate below the file number assigned to the  
registrant in connection with Rule 12g3-2(b): 82- N/A

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934,  
the registrant has duly caused this report to be signed on its behalf by the  
undersigned, thereunto duly authorized.

Bayer Aktiengesellschaft  
(Registrant)

Edgar Filing: BAYER AKTIENGESELLSCHAFT - Form 6-K

Date: January 31, 2002

By: /s/ ALEXANDER ROSAR

-----  
Name: Dr. Alexander Rosar  
Title: Head of Investor Relations

/s/ AXEL STEIGER

-----  
Name: Dr. Axel Steiger  
Title: Legal Counsel

EXHIBIT INDEX

1. One English-language version of a press release dated January 31, 2002, announcing acceptance by the European Medicinal Evaluation Agency of Bayer's filing of a marketing authorization application for vardenafil, a new drug for the treatment of erectile dysfunction.

2. One English-language version of a press release dated January 31, 2002, announcing the designated management group of Bayer CropScience AG, Bayer's planned new subsidiary.